Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Stock Is Jumping Today

By Keith Speights – Aug 26, 2021 at 11:50AM

Key Points

  • Inovio and its partner Advaccine received authorization from Brazil's health regulatory agency to initiate a late-stage study of experimental COVID-19 vaccine INO-4800.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The vaccine maker received some good news from Brazil.

What happened

Shares of Inovio Pharmaceuticals (INO -1.95%) were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's announcement that Brazilian regulators authorized the initiation of a phase 3 clinical study of COVID-19 vaccine candidate INO-4800.

So what

Inovio had previously announced in June that it was expanding a partnership with Advaccine Biopharmaceuticals Suzhou to conduct global phase 3 studies evaluating INO-4800. The company said at the time that the late-stage testing would primarily be done in Latin America and Asia. 

Gloved hands holding a syringe and a COVID-19 vaccine vial in front of a Brazilian flag.

Image source: Getty Images.

Today's news was welcomed by investors because they've waited a while for Inovio to advance INO-4800 into late-stage testing. The company had originally hoped to conduct a phase 3 study of its COVID-19 vaccine candidate in the U.S. However, Inovio was forced to change its plans earlier this year after the U.S. Department of Defense decided to discontinue funding for the U.S. late-stage study.

Now what

It's possible that more catalysts could be on the way for the vaccine stock. Advaccine is moving forward with two clinical trials in China evaluating INO-4800 and Sinovac's CoronaVac COVID-19 vaccine. Inovio also plans to report data for other pipeline candidates later this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$2.01 (-1.95%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.